[Treatment for recurrent hairy cell leukemia].

Area of Science:

• Hematology
• Oncology

Context:

• Hairy cell leukemia (HCL) is a rare B-cell malignancy.
• Purine analogue cladribine is a standard treatment for HCL.
• Understanding recurrence patterns is crucial for optimizing treatment strategies.

Purpose:

• To determine the frequency of recurrent hairy cell leukemia (HCL).
• To evaluate treatment outcomes for recurrent HCL.
• To identify patient subgroups with higher recurrence rates.

Summary:

• A study of 165 HCL patients treated with cladribine found a 22% recurrence rate.
• Younger patients (<45 years) had a significantly higher recurrence rate (47%) compared to older patients (9%).
• Combination therapy with cladribine and rituximab demonstrated high efficacy in treating early HCL recurrence.

Impact:

• Findings suggest rituximab should be considered in standard HCL therapy for young patients.
• Early intervention with combination therapy may improve outcomes for patients with early recurrence.
• This research contributes to personalized treatment approaches for HCL based on age and recurrence patterns.